The ability of a wide variety of compounds to disrupt normal endocrine homeostasis, and potentially, the physiological and reproductive capacity of an organism, is of great concern. Researchers at the University of California, Davis developed a novel, cell-based bioassay that detects compounds that impact the estrogen receptor signaling pathway.
This stably transfected recombinant human cell line responds to estrogenic chemicals with the induction of luciferase gene expression in a time-, dose-, and chemical specific manner and responds to antiestrogenic chemicals with the inhibition of estrogen-dependent gene expression.
Non-exclusive licenses are available for UC's property rights in this cell bioassay and patent rights in the luciferase reporter gene as it is utilized within the cell bioassay.
This cell bioassay system also contains components owned by the Promega Corporation. Licensees can acquire Promega permissions relevant to practicing this invention by executing a contract services agreement directly with Promega. UC can provide interested parties with a draft license agreement as well as a sample of the Promega contract services agreement.
This novel cell-based bioassay allows rapid and inexpensive screening, identification and characterization of estrogenic and antiestrogenic endocrine disrupting chemicals and extracts containing such chemicals. The assay can also provide an estimate of the relative estrogenic/antiestrogenic potency of a target/test chemical or an extract containing these chemicals.
endocrine disruptors, estrogenic chemicals, antiestrogenic chemicals, estrogen receptor signaling pathway